10 products found
Genmab A/S Products
-
Genmab Daratumumab - Human IgG1k Monoclonal Antibody (mAb)
Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.1 Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A subcutaneous formulation of daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) has been approved by ...
-
Genmab Ofatumumab - Human Monoclonal Antibody
Ofatumumab is a human monoclonal antibody which targets an epitope in the CD20 molecule encompassing parts of the small and large extracellular ...
-
Genmab - Tisotumab Vedotin
Tisotumab Vedotin is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis.1 It is composed of Genmab’s human monoclonal antibody (mAb) that binds to TF and Seagen’s ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE).1 TF is a transmembrane protein that is the main ...
-
Genmab DuoBody - Model PD-L1x4-1BB (GEN1046) - Proprietary Bispecific Antibody
DuoBody PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed by Genmab under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. DuoBody®-PD-L1x4-1BB is designed to elicit an anti-tumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB ...
-
Genmab DuoBody - Model CD40x4-1BB (GEN1042) - Proprietary Bispecific Antibody
DuoBody-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent T-cell activation, using an inert DuoBody® ...
-
Genmab DuoHexaBody - Model CD37 (GEN3009) - Bispecific IgG1 Antibody
DuoHexaBody-CD37 (GEN3009) is a bispecific IgG1 antibody created with Genmab’s proprietary DuoHexaBody technology platform, jointly owned by Genmab and AbbVie Inc. The DuoHexaBody platform combines the dual targeting of our DuoBody technology with the enhanced potency of our HexaBody technology, creating bispecific antibodies with target-mediated enhanced hexamerization. In preclinical settings, DuoHexaBody-CD37 has been shown to induce potent in ...
-
Genmab HexaBody - Model CD38 (GEN3014) - Novel Human Monoclonal Antibody
GEN3014 (HexaBody®-CD38) is a novel human CD38 monoclonal antibody incorporating Genmab’s HexaBody® technology. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen Biotech Inc. to develop and commercialize HexaBody®-CD38. In preclinical models of hematological malignancies, HexaBody®-CD38 demonstrated ...
-
Genmab DuoBody - Model CD3xB7H4 (GEN1047) - Proprietary Bispecific Antibody
DuoBody-CD3xB7H4 (GEN1047) is a proprietary bispecific antibody created using Genmab’s DuoBody® technology. B7H4 is an immune checkpoint protein expressed on malignant cells in various solid cancers including breast, ovarian and lung cancer. In preclinical studies, DuoBody-CD3xB7H4 was shown to induce T-cell mediated cytotoxicity of B7H4-positive tumor ...
-
Genmab Teprotumumab - Human Antibody
Teprotumumab is a fully human antibody created by Genmab under a collaboration with ...
-
Genmab Amivantamab - Human Bispecific Antibody
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both generated by Genmab. The antibody pair used to create Amivantamab was selected in collaboration between Genmab ...